<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00135954</url>
  </required_header>
  <id_info>
    <org_study_id>RUNMN01</org_study_id>
    <nct_id>NCT00135954</nct_id>
  </id_info>
  <brief_title>Treatment of Patients With Idiopathic Membranous Nephropathy</brief_title>
  <official_title>Treatment of Patients With Idiopathic Membranous Nephropathy at Risk for Renal Insufficiency: Comparison of Early Versus Late Start of Immunosuppressive Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Radboud University</source>
  <brief_summary>
    <textblock>
      Patients with idiopathic membranous nephropathy at risk for renal failure can be identified
      in an early stage by measuring urinary low molecular weight proteins and urinary
      immunoglobulin G (IgG). This study evaluates the possible benefit of early start of
      immunosuppressive therapy in these high-risk patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion Criteria:

        -  patients with idiopathic membranous nephropathy

        -  nephrotic syndrome

        -  normal renal function (serum creatinine [Screat] &lt; 1.5 mg/dl)

        -  elevated urinary beta2-microglobulin and IgG

      Immunosuppressive therapy consisting of:

        -  cyclophosphamide 1.5 mg/kg/day for 12 months

        -  prednisone orally, 0.5 mg/kg on alternate days for 6 months

        -  i.v. methylprednisolone 1000 mg on days 1,2,3, 60,61,62, 120,121,122

      Study Groups:

        -  early: immediate start of immunosuppressive therapy at the time patient is identified as
           high-risk

        -  late: start of therapy after deterioration of renal function (increase of Screat &gt; 25%
           and Screat &gt; 1.5 mg/dl)

      Main Outcome Parameters:

        -  serum creatinine

        -  remission of proteinuria

        -  period of nephrotic proteinuria

        -  major side effects: hospitalisations, infections
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1997</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>renal function (serum creatinine)</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>proteinuria</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>side effects</measure>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Glomerulonephritis, Membranous</condition>
  <arm_group>
    <arm_group_label>late intervention</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>cyclophosphamide and steroids started at time of renal insufficiency</description>
  </arm_group>
  <arm_group>
    <arm_group_label>early intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>immediate start of cyclophosphamide and steroids</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide and steroids</intervention_name>
    <description>comparison of difference in time of start of therapy</description>
    <arm_group_label>late intervention</arm_group_label>
    <arm_group_label>early intervention</arm_group_label>
    <other_name>prednisolone</other_name>
    <other_name>endoxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Idiopathic membranous nephropathy

          -  Serum creatinine &lt; 1.5 mg/dl

          -  Nephrotic syndrome

        Exclusion Criteria:

          -  Infection

          -  Instable angina

          -  Systemic disease

          -  Pregnancy

          -  Renal vein thrombosis

          -  Prior therapy with immunosuppressant agents

          -  Liver dysfunction

          -  Use of nonsteroidal anti-inflammatory drugs (NSAIDs)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jack F Wetzels, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Nephrology Radboud University Nijmegen Medical Centre</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2005</study_first_submitted>
  <study_first_submitted_qc>August 25, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2005</study_first_posted>
  <last_update_submitted>January 27, 2014</last_update_submitted>
  <last_update_submitted_qc>January 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>membranous nephropathy</keyword>
  <keyword>cyclophosphamide</keyword>
  <keyword>prednisone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis</mesh_term>
    <mesh_term>Glomerulonephritis, Membranous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

